Location History:
- San Carlos, CA (US) (2003)
- New York, NY (US) (1995 - 2006)
- Woodbridge, CT (US) (2006 - 2024)
Company Filing History:
33 out of 1,629 
7 out of 157 
5 out of 1,327 
Years Active: 1995-2024
Areas of Expertise:
Title: Joseph Schlessinger: Innovator in Therapeutic Antibodies and JAK2 Inhibitors
Introduction
Joseph Schlessinger is a prominent inventor based in New York, NY, with an impressive portfolio of 49 patents to his name. His work is primarily centered on the development of innovative therapeutic agents aimed at treating myeloproliferative disorders and KIT-mediated diseases.
Latest Patents
Among his latest patents is "Selective JAK2 pseudokinase ligands and methods of use." This patent showcases compounds that specifically regulate the activity of JAK2 by binding to its pseudokinase domain, JH2. These compounds are being explored as potential therapeutic agents for managing myeloproliferative disorders. Another significant patent is for "Anti-KIT antibodies and uses thereof." This invention involves antibodies that can immunospecifically bind to the human KIT antigen, impacting ligand-induced receptor phosphorylation and offering new avenues for treating KIT-mediated disorders.
Career Highlights
Joseph Schlessinger has had a distinguished career, contributing his expertise primarily through his roles at New York University and Sugen Incorporated. His research has led to breakthroughs in the pharmaceutical field and has significantly advanced our understanding of therapeutic targets related to cancer and blood disorders.
Collaborations
Throughout his career, Schlessinger has collaborated with esteemed colleagues, including Jan M. Sap and Benjamin L. Margolis. These partnerships have fostered innovative research and development initiatives, further solidifying his reputation in the scientific community.
Conclusion
Joseph Schlessinger is a vital contributor to the field of biomedical innovation, with his patents providing the foundation for advancements in therapeutic approaches for various diseases. His ongoing dedication to research and collaboration continues to impact the development of effective treatments, demonstrating the power of invention in the pursuit of medical progress.